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Abstract 
A key question in vascular biology is how the diversity of origin of vascular mural cells, namely 
smooth muscle cells and pericytes influences vessel properties, in particular the regional propensity 
to vascular diseases. This review therefore first describes the role and regulation of mural cells 
during vascular formation, with a focus on embryonic origin. We then consider the evidence that 
connects heterogeneities in smooth muscle cell and pericyte origins with disease. Since this idea has 
major implications for understanding and modelling human disease, then there is a pressing need 
for new model systems to investigate mural cell development and the consequences of 
heterogeneity. Recent advances arising from in vitro strategies for deriving mural cells from human 
pluripotent stem cells as well as from the zebrafish model will be discussed and the medical 
relevance of these discoveries will be highlighted. 
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1. Introduction 
Cardiovascular diseases such as myocardial infarction and stroke are the main causes of death in 
Europe1. The vast majority of these cases are secondary to atherosclerotic disease of the arterial 
wall.  Other diseases of the vessel wall such as aortic aneurysms are less common but can have 
devastating consequences, often in young people with no warning. The high prevalence and severity 
of arterial diseases has resulted in an urgent need to better understand the underlying biology of the 
vessel wall in both health and disease.  
An increasing body of work suggests that developmental factors continue to influence the response 
of adult blood vessels under physiological and pathological conditions. The vasculature is 
heterogeneous in terms of structural composition and function2. Moreover there are striking 
regional heterogeneities in disease development that are thought to be governed by hemodynamic 
factors as well as vessel structure3. Although structure and anatomy are developmentally 
determined, the prevailing hemodynamic view does not take into account the multiple different 
embryonic origins of vascular mural cells, namely smooth muscle cells (SMC) and pericytes, and the 
consequences of this heterogeneity on disease4,5.  
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This review will therefore initially discuss the development and regulation of SMCs and pericytes 
during blood vessel formation, with an emphasis on their embryonic origins. We will accordingly 
focus on lineage specific variations in the signalling pathways that regulate mural cell development 
and impact on their distinct functional properties. These functional differences may lead to distinct 
differences in pathological responses and we will next emphasise the evidence connecting 
heterogeneities in SMC origins with disease and will examine both clinical and experimental studies. 
Since the idea of a developmental basis for the vascular disease response has important 
connotations for our understanding of human disease and for vascular regenerative medicine, then 
new experimental model systems that would allow us to examine vascular cell development and the 
consequences of mural cell heterogeneity, are urgently required. In recent years, we and others 
have progressed human pluripotent stem cells and the zebrafish model for investigating mural cells 
of distinct embryonic origins and their role in vascular development and disease. These model 
systems will be discussed in detail and we will highlight the translational potential of these exciting 
new tools. 
2. Vascular mural cell embryonic development 
Vascular mural cells are an essential component of the vasculature and are required for the normal 
development and homeostasis of mature blood vessels. The initial events in vascular development 
are differentiation of a primary endothelial vascular plexus from angioblasts which then undergoes 
angiogenic remodelling6,7. Vascular mural cells are recruited by developing blood vessels in a process 
called vascular myogenesis8. During this process, mesenchymal precursors are recruited by 
endothelial cells and ensheathe established blood vessels9–12.  
Vascular mural cells have been traditionally classified into vascular SMC and pericytes depending on 
their density, morphology, location, and expression of specific markers13–16. Vascular SMCs are found 
mainly in medium and large blood vessels where a continuous single or multilamellar SMC layer 
surrounds the endothelial cell lining and provides contractility to modulate blood flow and stability. 
SMCs are separated from the endothelium by a basement membrane. SMCs secrete most of the 
extracellular matrix in the media, consisting mainly of elastin and fibrillar collagens I and III, which 
together with fibroblast-derived adventitial collagens largely determine the mechanical properties of 
the vessel wall2. Other common matrix components include laminin, collagen IV, nidogen, perlecan, 
and fibulins17–19. Secretion of extracellular matrix from SMCs is essential for normal function and 
development while matrix abnormalities are commonly seen in vascular disease20,21. Modulation of 
the mural cell phenotype by extracellular matrix components is dependent on their binding to 
specific integrin and non-integrin receptors22,23. 
Pericytes are mural cells found in microvessels such as terminal arterioles and capillaries, with high 
densities particularly in the brain, eye and kidney24–27. Pericytes are isolated cells and unlike SMCs do 
not form a continuous layer. Their key feature is that pericytes are embedded within the basement 
membrane and make direct contact with the underlying endothelial cells. Functionally, their 
predominant roles likely include regulating capillary permeability, endothelial stabilisation and 
microvascular contractility28.  
It is important to appreciate that SMC and pericytes are found as a continuum of mural cells, with a 
gradual change in morphology and features as the vasculature branches into smaller vessels. Indeed 
there are no specific molecular markers that unequivocally distinguish pericytes from SMCs and 
validated markers for pericytes such as RGS5, CD146, NG2 (CSPG4), PDGFR-β and desmin may all be 
expressed in SMCs under a variety of conditions29. For these and other reasons, pericytes and SMCs 
are often thought of as related cell types with developmental links30. For the purposes of this review, 
we will use the general term ‘mural cell’ when referring to both SMCs and pericytes or when the cell 
type has not been clearly defined.  
Vascular SMCs represent a mosaic tissue produced from multiple unique and non-overlapping 
developmental origins31 (figure 1). Pioneering studies conducted in avian embryos showed the first 
indication that vascular smooth muscle origins might be diverse. SMCs in the great vessels were 
traced back to a distant source of progenitors at the dorsal surface of the cranial neural tube32,33. We 
now know that SMCs of the aorta and many of its proximal branches have multiple different 
developmental origins. The ascending aorta and arch, the pulmonary trunk, the brachiocephalic, 
subclavian and carotids are all derived from the neural crest. The secondary heart field contributes 
to a domain overlapping neural crest derived SMCs at the base of the aortic root34 while the 
descending aorta is derived from somites35.  
Although most of the work on ontology has been carried out on SMC, in cases where studies have 
been carried out on the embryonic origin of pericytes, they have been found to have a concordant 
origin with the SMC in the larger vessels supplying that territory. The majority of the SMC and 
pericytes in the head region, including those that vascularise the central nervous system, are neural 
crest derived, as demonstrated in chick-quail chimeras24,36 and indicated by marker expression in 
mice37. Recent studies on thymus development demonstrated that also the mural cells in the thymus 
are derived from neural crest. The origins of vascular SMC in the gut38 and liver39 have been mapped 
to the mesothelium, the single-layer squamous epithelium that lines the coelomic cavities and its 
organs and originates from the lateral plate mesoderm. Coronary vessel mural cells in the heart 
appear to have a similar development. Here, the epicardial mesothelium is thought to give rise to 
cardiac mesenchymal cells, including coronary SMCs and pericytes. The case of pulmonary mural 
cells is interesting, as despite the proximal large pulmonary vessels originating from the neural crest, 
the more distal pulmonary artery SMCs and pericytes, consistent with vessels in other coelomic 
organs appear to be derived from pulmonary mesothelium40.  Further studies are still required to 
determine to what extent there is concordance between SMC and pericyte ontology and whether 
there are any vascular beds, in normal development or in response to disease processes that result 
in discordant origins for these mural cells.  
3. Signaling pathways implicated in the developmental of mural cells 
Mural cells are significant contributors to vascular development and vessel remodeling as well as 
disease. Although a unique list of markers defining mural cells is a desiderata for many biologists and 
clinicians such effort remains a puzzling task (reviewed in detail by Shen and McCloskey30). Some of 
these markers vary between pericytes and vascular SMCs and change due to the heterogeneity and 
plasticity of these cells during time and space. The anatomical relationship between mural and 
endothelial cells suggests close interactions involving paracrine or juxtacrine signaling but also less 
studied factors such as mechanical forces, cell-matrix contacts and lipid signaling. Here we 
summarize the major endothelial-mural cross-talk signaling described so far. Importantly, the role of 
many of these pathways varies depending on the embryonic lineage of the mural cells. 
3.1 PDGF-BB/PDGFR-β 
PDGF receptor (PDGFR)-β expression is considered as one of the first indicators of mural cell 
lineage41–43. PDGF-BB is released from angiogenic endothelial cells and binds to PDGFR-β expressed 
on the surface of emerging mural cells. As a result, PDGFR-β-positive mural cells (or their 
mesenchymal progenitors) are recruited with the angiogenic sprouts and microvessel wall41,44. 
PDGFR-β is expressed broadly by pericytes and developing vascular SMCs, and PDGF-BB probably 
plays a role also in the proliferation and differentiation of aortic and venous vSMCs. Knockout of the 
pdgfb or pdgfrb genes in mice results in virtually identical phenotypes and perinatal lethality 
resulting from vascular dysfunction caused by mural cell deficiency45,46. The degree of this deficiency 
varies extensively between different organs, suggesting that other signaling pathways may play a 
similar role to that of PDGF-BB/PDGFR-β in mural cell recruitment47–49. Regional variations in other 
signaling pathways have been shown to depend on embryonic origin (see TGF-β and Notch sections) 
suggesting a possible developmental explanation for the regional variation in PDGF-BB signaling. 
3.2 TGF-β signaling 
Cytokines of the transforming growth factor-β (TGF-β) family, including TGF-βs, bone morphogenic 
proteins (BMPs), activins, and nodal, play crucial roles in embryonic development and adult tissue 
homeostasis by regulating cell proliferation, survival, and differentiation, as well as stem-cell self-
renewal and lineage-specific differentiation 50. In the cardiovascular system, TGF-β signaling has 
been shown to play crucial roles in vasculogenesis, angiogenesis, and lymphangiogenesis including 
regulation of mural cell differentiation, proliferation and migration 51. Recently, pericytes have been 
suggested to differentiate from tissue myeloid progenitors in the skin vasculature through TGF-β 
signaling 52. TGF-β pathways also interact with other key vascular signaling pathways. For example, in 
cerebral endothelial cells the TGF-β/SMAD4 pathway has been shown to cooperate with Notch/RBP-
Jk pathway to regulate N-cadherin expression and stabilize contacts between endothelial cells and 
pericytes 53.  
Importantly, studies have shown a specific requirement for Smad254 and Mkl255,56 in development by 
the neural crest-derived aortic arch SMCs. Meanwhile in adult SMCs, TGF-β elicits key differences in 
the response of SMC of different embryonic origins with proliferation of neural crest-derived aortic 
arch SMCs and suppression of proliferation in mesoderm derived SMCs57. Additionally, angiotensin II 
signaling which enhances TGF-β signaling also has a lineage dependent effect on SMC. Owens et al 
demonstrated a divergent effect of angiotensin II infusion with SMC hyperplasia in the ascending 
aorta and hypertrophy in the descending aorta58. These findings highlight that the complex and 
pleiotropic actions of various growth factor signaling cascades on SMC development and function 
are further modified by their embryonic origins. 
3.3 Notch signaling 
In the development and differentiation of vascular SMCs, the roles of the Notch pathway can be 
categorized into two different types: constructing a mature blood vessel wall and artery-vein 
differentiation 59. Once recruited to endothelial tubes, Notch ligands in endothelial cells can induce 
Notch activation in mural cells, which promotes integrin adhesion to endothelial basement 
membrane and initiates maturation and differentiation60. Besides, the Notch activation in vascular 
SMCs can further lead to the increased expression of Notch ligand, Jagged1 which allows for lateral 
induction of Notch signaling by homotypic vascular SMC-SMC interactions through multiple layers of 
smooth muscle to promote SMC differentiation61. Furthermore, Notch can also be closely tied to the 
many possible phenotypic endpoints of vascular SMCs 59. For example, Notch signaling in vascular 
SMCs can promote contractile differentiation and also there are contrasting data supporting that 
Notch can promote or inhibit vascular SMC proliferation in vitro and in vivo62. A key factor that may 
explain opposing responses could be the embryonic lineage of the SMC. Recent studies have shown 
that SMC of different embryonic origins respond differently to notch3 depending on developmental 
stage63. In the zebrafish model Notch3 enhances brain vascular integrity by regulating pericyte 
numbers 64. 
Several reports, support a role of Notch signaling for vascular SMC and/or pericyte survival, 
proliferation, differentiation and even migration65–67. Further evidence proposes the role of Notch-
PDGFBB interactions in pericyte differentiation with Dll4 and PDGF-BB that can convert skeletal 
myoblasts to pericytes 68. These data indicate that Notch is required for mural cell recruitment to the 
blood vessel wall in response to PDGF-BB signal. 
Overall, both endothelial cells and mural cells express several Notch receptors and ligands indicating 
that this signaling pathway is crucial in both angiogenesis and vascular maturation. Hemodynamic 
and environmental conditions have been shown to modulate this pathway as well, altering the 
response of endothelial cell and SMC physiology. Mutant analyses of Notch receptors and its ligands 
in human, mice and zebrafish also support different functions of this pathway among species. 
Overall, our understanding on how Notch pathway regulates the association of mural cells and 
endothelial cells is still very limited and far from being completely decoded. 
 
4. Developmental heterogeneity and disease  
The presence of different embryonic origins for distinct mural cell populations or vascular beds 
raises a crucially important question: does embryonic origin impact regional susceptibility or 
development of disease? In this section we review clinical studies that suggest that embryonic origin 
may have a role in regulating disease development and then examine experimental data from 
animal models that supports this hypothesis.  
Studies by deBakey in cardiac patients and the Pathobiological Determinants of Atherosclerosis in 
Youth (PDAY) study suggest a regional heterogeneity in disease development. deBakey and Glaeser 
69 reviewed 5,568 patients who initially had documented occlusive atherosclerotic disease in a single 
region and required surgery and had repeat angiography to measure progression. These patients 
were divided into 4 arterial disease categories: coronary, aortic branches, abdominal viscera and 
terminal abdominal aorta and branches. After 25 years follow up, different arterial beds showed 
different responses to common risk factors. The patients in this study were selected as already 
having established occlusive disease. The PDAY study on the other hand examined unselected young 
people who had died of noncardiac reasons and compared atherosclerotic disease in different 
regions70,71. The investigators found that systemic risk factors had differential effects on disease 
development in different vascular regions. For example males had more fatty streaks in the right 
coronary artery than women but women showed increased early disease in the aorta. Smoking 
predisposed to increased fatty streaks only in the abdominal aorta while glycated haemoglobin 
levels predicted early disease in the right coronary artery only. Together the findings from the 
deBakey and PDAY studies suggest that different vascular regions have different susceptibilities to 
common systemic risk factors.  
It should be noted that these findings do not inform us as to the cause of the differing 
susceptibilities to disease. One possible mechanism, as posited in this review article, is the distinct 
embryonic origins of the SMC leading to differences in responses to disease mediators between 
different vascular regions. Other causes could include differences in vessel wall structure. For 
example, Sims found an increased number of discontinuities in the internal elastic laminae of 
coronary arteries versus internal mammary arteries. The greater elastic lamina discontinuities were 
associated with increased cellular content in the coronary intima, which may predispose  the 
coronary artery to develop atherosclerosis compared to the internal mammary72. It is of course 
possible that these differences in elastic tissue structure are also developmentally mediated. 
Another vascular disease that has characteristic distribution is aortic aneurysm and dissection. These 
are categorised typically as abdominal or thoracic aortic aneurysms (Figure 2). Abdominal aneurysms 
are associated with many of the same risk factors as for atherosclerosis, while thoracic aneurysms 
have an association with genetic syndromes (e.g. Marfan syndrome) and frequently present in the 
aortic root and ascending aorta. In particular, there is increasing evidence for a possible role of 
different SMC lineages in the development of thoracic aortic aneurysms. 
Since the majority of elastin is deposited in fetal and early neonatal life, it seems differences in 
vessel wall mechanical properties are developmentally programmed and again raise the possibility of 
embryonic lineage having a role. The aortic media is composed of extracellular matrix and SMC. 
Elastic fibres and collagen make up at least 50% of dry weight73. Elastic fibres give rise to aortic 
elasticity while collagens provide overall stiffness and strength. These mechanical parameters vary 
along the course of the vascular tree (examples of local variability). Of note the aorta provides 65% 
of all arterial compliance and the majority of this is in the ascending aorta and arch74 while the 
ascending aorta has the highest elastin content75,76. Moreover, while these variable local mechanical 
properties may be advantageous for pump function and blood distribution, they may predispose to 
aortic disease especially at transition zones between different SMC lineages.   
A key requirement for development of aortic aneurysm and dissection is medial weakness and 
predisposing factors include hypertension, genetic connective tissue disorders, pregnancy, 
atherosclerosis and arterial inflammation. If embryonic origins predispose different regions of the 
aortic wall to produce differing amounts of structural proteins or distinct cellular behaviour, then the 
outcome may be regional differences in strength and disease development. In this context, the entry 
intimal tear in dissecting thoracic aneurysms is usually found in the ascending aorta (29%) or at the 
sino-tubular junction (29%) in type A dissections77, an area where SMC of different embryonic origins 
are juxtaposed. 
The interaction between SMC populations of different embryonic origins has been proposed to be 
detrimental in some genetic aortopathies. Increased TGF-β signalling has been invoked as a driver of 
aortic aneurysms in Marfan syndrome78. It is then paradoxical that in Loeys-Dietz syndrome, a 
related aortopathy syndrome, that the mutations in TGFbRI or TGFBRII are loss of function 
mutations. Although in vitro studies show reduced signalling through these mutant receptors, there 
is evidence of increased Smad2 phosphorylation in late stage aneurysms and the observations have 
been reconciled by proposing compensatory increases in TGF-β release/activation by one SMC 
lineage that leads to excess signalling in adjacent SMC from a different lineage79,80. While the precise 
nature of TGF-β in aneurysm development is now subject to considerable debate81–84, the concept of 
adjacent populations of SMC from different lineages leading to the development of a maladaptive 
extracellular milieu for one or both of the populations which predisposes to disease is an interesting 
idea that needs further experimental validation. Certainly distinct regions of SMC are juxtaposed in 
the aortic root and at the aortic isthmus, both regions that are highly susceptible to an intimal tear77.  
In addition to clinical observations, a number of animal studies have suggested that regional 
embryonic heterogeneity may predispose to disease. Aortic arch SMC derived from the neural crest, 
were shown to have a greater propensity to calcify compared to the mesodermal derived 
descending aorta, using either aortic explants under high phosphate conditions or in vivo in a MGP 
null mouse model85. The authors concluded that the aorta was developmentally regionalised and 
this heterogeneity had an effect on pathological calcification.  Similarly, Pruett et al86 identified that 
Hox genes identified positional identities in the vasculature and that transgenic overexpression of 
Hoxc11 resulted in region-specific remodelling of the arterial tree87. Meanwhile Andres and 
colleagues identified regional differences in Hox family member gene expression and NFkB activity 
that anti-correlated in the aortas of atherosclerosis susceptible mice88. They further demonstrated a 
reciprocal inhibitory action between NFkB and HoxA9, thus identifying a possible regulatory 
mechanism that defined an atherosclerosis susceptible aortic arch with high NFkB activity and low 
HoxA9 expression, while conversely the atherosclerosis-resistant descending thoracic aorta had low 
NFKB activity and high expression of HoxA9. The most intriguing finding in this study however was 
that similar differences in Hox family member gene expression patterns including HoxA9 were 
detected between SMC generated in vitro from neuroectoderm (analogous to the aortic arch) versus 
paraxial mesoderm (analogous to the descending aorta). This finding suggests that at least some of 
the differences in gene expression that define regional vascular susceptibility to disease are 
programmed during development, since there were no confounding factors such as flow or vessel 
structure in the in vitro studies.  
Despite our focus on embryonic origin, it should be remembered that a major determinant of the 
site specific nature of vascular disease development is regional differences in hemodymamic forces. 
In particular for the development of atherosclerosis, low shear stress89 and turbulent flow are 
thought to be important drivers of disease location. Accordingly mouse models of atherosclerosis 
show increased disease at branch points and along the lesser curvature of the aorta. Indeed there is 
considerable evidence of differential hemodynamic profiles predisposing different endothelial 
populations to display distinct responses to systemic risk factors3. Thus we propose that the effect of 
embryonic origins is to provide a basal regional susceptibility to disease that then responds to highly 
variable local hemodynamic cues. 
 
5. New models to study SMC and pericyte developmental heterogeneity 
5.1 Human pluripotent stem cells  
Generation of mural cells from embryonic stem cells and induced pluripotent stem cells, together 
termed pluripotent stem cells (PSC), offers the opportunity to recapitulate many of the 
developmental steps that take place in the embryo. In particular, the availability of human PSCs 
enables the study of SMC and pericyte development and disease in a human context. A number of 
groups have developed protocols to generate mural cells from PSCs and these have been reviewed 
recently by Dash et al90 and Sinha et al91. These approaches initially depended on spontaneous 
differentiation in embryoid bodies, which results in a heterogenous mixture of different types of 
SMCs and/or pericytes. Further developments in in vitro methods included the use of stromal feeder 
cells, or specific matrix coatings such as collagen IV, or a combination of growth factors along with 
serum to induce SMCs. Although these systems were efficient in producingmural cells, the 
limitations included the lack of chemically defined systems and difficulties in relating the in vitro 
stages to known developmental events in the embryo. In addition the phenotypic characterisation of 
the resultant smooth muscle-like cells and their precise developmental stage and functionality were 
not always fully defined.  
Indeed, given that the primary distinction between SMC and pericytes is related to endothelial cell 
contact and sharing of the endothelial basement membrane, it can be difficult to distinguish 
between these cells in conditions where morphological criteria are lacking such as in vitro. Thus the 
majority of in vitro protocols use molecular markers to identify the cells, although as most of these 
are shared between SMC and pericytes, then the precise identity of in vitro generated mural cells 
can be indeterminate92. In many protocols, cells were shown to express mature SMC specific 
markers such as MYH11 and SMTN93,94, suggesting the generation of bona fide SMCs although such 
marker expression can be limited and variable or poorly characterised95, and may reflect a degree of 
plasticity of PSC-derived mural cells in vitro. Alternatively, mural cells that did not express MYH11 or 
SMTN have been labelled either as general mural cells92 or as pericytes96, although given the 
overlapping nature of pericyte markers the latter may also represent immature SMCs.  
One of the biggest limitations was that the embryonic origin of mural cells in these in vitro systems 
was relatively neglected.  To address this limitation, we described the use of a chemically defined 
system that used human PSCs to first generate neuroectoderm, lateral plate mesoderm and paraxial 
mesoderm, the 3 embryonic tissues that give rise to the majority of vascular SMCs97. We then 
generated lineage specific SMCs from these intermediate embryonic tissues that displayed all the 
markers and functionality of contractile SMCs but differed in behaviour in the same way as already 
described for SMCs from different aortic or vascular regions98. For example, during development 
MKL2 is required specifically by neural crest derived SMCs, while these same SMC in the adult 
proliferate in response to TGF-β while mesoderm-derived SMCs do not. The lineage specific hPSC-
derived SMC platform was able to reproduce these differences in the need for MKL2 during 
development or in the response to TGF-β in neuroectoderm-derived SMCs compared to those from 
mesoderm. This system was further refined by the generation of epicardium, the precursor for 
coronary SMCs, from the lateral plate mesoderm99. Epicardial cells expressed multiple epicardial 
markers and when injected in ovo, were able to localise to their subepicardial niche in a chick model. 
Taken together, these findings supported the validity of an in vitro lineage specific system. 
In addition to validating known differences between different SMC populations, a key requirement 
for such an in vitro model is to make novel predictions that can be tested in vivo or in primary SMC 
cultures. Our in vitro model was firstly able to predict the differential proteolytic responses of 
different regions of SMC from different regions of the rat aorta when treated with IL-1β97. Indeed we 
hypothesise that this differential degradation of underlying extracellular matrix in different aortic 
regions may predispose to increased wall stress and intimal tear at sites where there is a 
juxtaposition of two different SMC lineages. Secondly, further in vitro studies revealed a key role for 
Notch3 in SMC development specifically from the neuroectoderm lineage63. While this finding 
predicts abnormalities in neural crest derived SMC in vivo, the Notch3 null mouse had not been 
shown to have any vascular abnormalities during fetal development100. However, a more detailed 
analysis unearthed a mild phenotype with reduced maturation of carotid SMC in Notch3 null 
embryos at E13.5 compared to wild type controls63. Finally, gene expression studies from this in vitro 
model also predict a diversity of functions between SMCs of distinct embryonic origins. For example, 
the increase in genes related to calcification in neuroectoderm-derived SMC97 is consistent with the 
high frequency of calcification in the ascending aorta and aortic arch101. Further differences in gene 
expression and corresponding functional differences in vitro between the different lineages, such as 
SMC migration or inflammatory activation, also warrant investigation as to their in vivo relevance. 
Together these findings reinforce the validity of this lineage specific approach and highlight the need 
to consider embryonic origins when considering SMC biology. 
One of the most exciting uses of human PSC-derived SMC systems is in modelling human vascular 
diseases in vitro using patient-derived induced PSCs. Since it is generally difficult to obtain human 
vascular tissues, and tissues obtained at the time of surgery usually represent end-stage disease, 
then an in vitro system enables an unprecedented analysis of early mechanisms that may be driving 
the disease and be amenable to therapy. Initial studies on SMCs examined genetic diseases such as 
Hutchinson-Gilford Progeria syndrome102,103 and Williams-Beuren syndrome104. These resulted in key 
insights into the cellular and molecular pathologies that develop in these conditions and the in vitro 
platform then offers a system to screen for and test new therapies. However, limitations such as the 
precise type of SMC generated, an inability to account for the localised nature of some of these 
conditions and a lack of rigorous isogenic control lines remained105. 
We recently addressed some of these limitations using the lineage specific system of SMC 
generation to model the aortic abnormalities in Marfan syndrome. SMCs derived from iPSCs 
generated from two patients with severe aortic disease recapitulated multiple phenotypical 
abnormalities seen in the Marfan aorta including increased matrix metalloproteinase activity, 
disruption and loss of extracellular microfibrils, reduction in SMC contraction and proliferation and 
increased SMC death106. We identified increased TGF-β signalling through both canonical Smad 
pathway and the non-canonical ERK1/2 and p38. These structural, biochemical and functional 
abnormalities were reversed on CRISPR/Cas9-mediated correction, verifying that the disease 
phenotypes seen were indeed caused by the single nucleotide mutation. Importantly, treatment 
with losaratan – an angiotensin receptor blocker that was highly promising in mouse studies, but 
disappointing in recent clinical trials – was only able to rescue the extracellular matrix and 
proliferative phenotypes, while cell death was regulated independently by p38 and KLF4. Cyclic 
stretch exacerbated the disease phenotype through a β1-integrin mediated pathway, thus validating 
a mechanosensory component of the disease mechanism. Intriguingly, the phenotypic abnormalities 
were most severe in neural crest-derived SMCs, suggesting a developmental explanation for the 
location of the aortic aneurysms in Marfan syndrome in the aortic root, ascending aorta and arch. In 
fact the earliest onset of the aneurysm in this condition is in the aortic root, a region with extensive 
overlap between secondary heart field and neural crest-derived SMCs. These observations support 
the hypothesis that juxtaposition of SMCs of different embryonic origins may potentially be 
detrimental to vascular health, and reinforce the importance of using lineage specific SMC systems 
for disease models. 
These iPSC-based strategies could also be used with other genetically mediated aortic syndromes, 
such as Loeys-Dietz or vascular Ehlers-Danlos syndromes. Given the principal location of Loeys-Dietz 
aneurysms in the aortic root and ascending aorta, it is likely that as for Marfan syndrome, there will 
be differences in disease susceptibility in SMC of different embryonic origins. Indeed, the ‘Loeys-
Dietz paradox’ of loss of TGF-β function mutations leading to increased TGF-β signalling is postulated 
to involve maladaptive compensatory responses in juxtaposed SMC populations79,80. This hypothesis 
could be tested in vitro using lineage specific SMC from patient-derived iPSCs. Conversely, the 
aneurysmal distribution in vascular Ehlers-Danlos is more widespread and so it would be predicted 
that all SMC lineages would display a disease phenotype equally. A lineage based disease modelling 
approach also has value beyond single gene disorders. In the aortopathy associated with bicuspid 
aortic valve107, there were differences in contractility and maturation of SMCs from neural crest vs 
paraxial mesoderm, including reduced canonical TGF-β signalling and increased mTOR activity in  
neural crest-derived SMC. These findings shed light on the underlying abnormalities in this relatively 
common condition and again suggested a developmental explanation for the distribution of the 
disease.  
Although many diseases have been studied using mouse or other animal models, these are not 
always representative of human physiology or disease. In particular, animal models cannot replicate 
the genetic context of patient derived cells that may be essential for disease development. For 
example, genetic variants that affect noncoding regions of the genome frequently have no 
corresponding mouse sequences. This is clearly illustrated by the findings of the recent genome wide 
association studies. These have so far identified at least 58 variants that are associated with 
cardiovascular disease. However, the majority of these variants are located in noncoding regions, 
which are poorly homologous in mice, and the genes involved in the pathology are unknown108. 
Using hiPSC with and without the risk haplotypes may enable these variants to be investigated in a 
human vascular context.  
Recently the ability to efficiently carry out site specific single nucleotide changes using CRISPR/Cas 
(clustered regularly interspaced short palindromic repeats-CRISPR associated) methods109 offers a 
powerful tool to validate causal variants110. This approach is based on a bacterial defence system 
adapted for use in mammalian cells111,112. Bacteria respond to infecting viruses by incorporating 
foreign DNA into the bacterial genome as clusters of short repeats which can be used to provide 
adaptive immunity. On reinfection, these clusters are transcribed and act as guides for Cas proteins 
that will target and interfere with the identified invading DNA. Using the same approach, mutations 
may also be introduced into wild type PSCs to create disease models obviating the need for patient 
samples. It should be noted however that one advantage of patient derived iPSCs is that the extent 
of clinical disease is usually clear; with ‘patient-free’ in vitro engineered disease models it would not 
be clear in advance whether the genetic background would be permissive for disease development. 
Other translational fields where SMC lineage may be relevant include vascular regeneration and new 
drug testing. hPSC-derived SMC are being used to regenerate or tissue-engineer both large vessels 
and the microvasculature113–115. To date no studies have compared the use of different lineage 
specific SMC, although given their distinct biological properties it is likely that there will be distinct 
functional responses depending on the mural cell origin resulting in different vessel properties. As a 
first attempt at this question, Bargehr and colleagues found that SMC derived from hPSCs supported 
network formation by endothelial cells in vitro and that the extent of support varied according to the 
embryonic origin of the SMC116. Differential expression of a range of angiogenic factors such as 
midkine, mediated the differential supportive properties of distinct SMC lineages. While the 
developmental significance of these findings is unclear, the results have implications for 
regenerative medicine strategies where vascular regeneration is planned. In terms of drug testing, 
lineage specific neuroectoderm-derived SMC have recently been used in an endothelial cell co-
culture system that includes physiological or pathological shear stress when testing compounds117. 
While this study was the first to compare hiPSC-derived SMC and endothelial cells with primary cells 
and validated the use of these in vitro generated cells for drug testing, further studies comparing the 
responses of multiple different lineages would be revealing.  
Although PSC based strategies for generating lineage specific SMCs offer great promise for 
understanding regional variations in disease development, the underlying mechanisms and testing 
new drugs, there are a number of limitations that need to be borne in mind when using this 
approach. The most important consideration is to what extent the in vitro findings reflect in vivo 
events. It is inevitably difficult to replicate the multiplicity of other non-SMC that may interact with 
SMC in the vessel wall, although endothelial cell co-cultures are a first step in this direction117. 
Furthermore effects of vessel wall structure, blood flow and cyclic stretch should be borne in mind 
and can be modelled in vitro to some extent106,117,118. Indeed tissue engineered vessels offer the 
opportunity to study several of these factors in an integrated manner, although they suffer from 
usually being low throughput and time-intensive113. Another consideration is the extent to which 
embryonic differences are maintained in the adult vasculature. Pfalzgraf and colleagues have 
described a loss of the transcriptional and phenotypic differences seen in embryonic aortas when re-
examined in adult mice119. These findings are somewhat controversial due to possible cellular 
heterogeneity in the adult tissues used for transcriptional analyses and the use of immortalised SMC 
lines, and need further validation. Nevertheless, they raise the interesting idea of phenotypic 
convergence in adult vessels, although since embryonic genes are frequently re-expressed in 
disease, then differences mediated by embryonic origin may still have a role in regulating adult 
disease.  
 
5.2 Zebrafish as model system to study mural cell origin in vertebrates  
The zebrafish (Danio Rerio) has emerged in recent years as an excellent vertebrate model organism 
to study a wide variety of biological processes. Some of the advantages of the zebrafish model 
system include high fecundity, external fertilization, rapid development and optical clarity. Last, but 
not least, zebrafish has low-cost maintenance compared to other vertebrate model systems. The 
importance of zebrafish for cardiovascular research relies on some unique characteristics such as the 
early development of a functional cardiovascular system (beating heart, aorta, cardinal vein, and 
blood) that is already formed by 24 hours post fertilization (hpf). Since the zebrafish embryo is 
relatively small and aquatic, oxygen can diffuse passively through tissues and thus embryos can live 
up to three days without a functional cardiovascular system120,121. This allows genetic manipulation 
of cardiovascular development for longer than would be possible in mammals, where the absence of 
a functional cardiovascular system is fatal during its early development.  
A major advantage of the zebrafish system is the combination of optical clarity and simple 
transgenics, which has resulted in a powerful model system for analysing the molecular basis of 
development. Until 5 days post fertilization (dpf), zebrafish embryos are nearly transparent, allowing 
in vivo visualization (even at single cell resolution) of the heart, blood vessels, as well as other 
tissues, without instrumentation or manipulation other than the use of a stereomicroscope. 
Furthermore, the generation of tissue-specific transgenic lines is relatively easy. Such a method 
usually uses a native tissue-specific promoter to drive expression of a fluorescent reporter protein, 
such as green fluorescent protein or mCherry. Coupled with impressive optical clarity, these 
transgenic lines allow observation of in vivo cellular behaviour in a way impossible in other models. 
Transparent zebrafish embryos are also well suited for in vivo time-lapse imaging. The fast 
acquisition speed of a spinning disk and 2-photon confocal microscopy reduces the recording time 
significantly when millimeter-sized embryos need to be imaged at high resolution and at short time 
intervals. Light Sheet Fluorescence Microscopy could also be very useful in zebrafish122. These 
attributes, including the possibility of carrying out gain- and loss-of-function studies, have led to the 
emergence of the zebrafish as an excellent embryological model that provides a unique opportunity 
to uncover novel insights into the molecular genetics of endothelial and mural cell development123.  
It should be noted that in early zebrafish development, due to the lack of specific reagents for 
characterization of vascular basement membrane as well as the lack of selective markers for 
mesenchymal cells associated with blood vessels, it is difficult to label cells definitively as pericytes 
or SMCs so we use the more general term: mural cell. 
In the beginning we showed that zebrafish embryos develop mural cells that share many of the 
morphological, molecular and functional characteristics of mammalian mural cells 124. This Initial 
investigation has been essential to other investigations using the zebrafish model to study the 
biology of vascular mural cells64,125,126. Early zebrafish mural cells expressed characteristic 
SMC/pericyte markers such as PDGFR-, ACTA2 and Transgelin. Other well-known mammalian 
pericyte markers such as NG2, RGS5 and CD146 has never been tested in zebrafish due to the lack of 
species-specific reagents. Dorsal aorta mural cells appeared to originate from the lateral plate 
mesoderm on the ventral side of the dorsal aorta, suggesting evolutionary conservation of 
embryonic origin and function124,125. Subsequently, specific transgenic fish were generated and used 
to trace the live development of mural cells in embryonic and larval stages. Acta2, pdgfr and tagln-
based transgenic animals are currently available to follow vascular SMC and pericyte recruitment 
from early stages of development to adulthood125–128.  
Recently, by using live imaging of mural cells and by lineage tracing in vivo Ando and colleagues 
illustrate the developmental origins and biology by which mural cells develop and cover endothelial 
cells in zebrafish embryos125. They show that in cranial vessels and in the aortic arches mural cells 
were derived from neural crest cells, while vessels in the hind brain were of mesoderm origin. In the 
trunk vasculature, mural cells derived from mesoderm covered the ventral side of the dorsal aorta 
(DA), but not the posterior cardinal vein124,125. Furthermore, live imaging clarified that mesoderm-
derived mural cells are induced and recruited at the ventral portion of the dorsal aorta and then 
migrate from the dorsal aorta around intersegmental vessels (ISVs) preferentially covering arterial 
rather than venous ISVs. These findings suggest that arterial endothelial cells promote greater mural 
cell recruitment and maturation compared to their venous counterparts125,128.  
During cardiovascular development mural cells appear shortly after the onset of circulation of blood 
flow129. As consequence, mural cell coverage and mechanical signalling promote accumulation of 
extracellular matrix and vessel’s wall maturation2. Recently, the role of flow-dependent forces and 
primary cilia in vascular mural cell coverage of developing vessels in zebrafish embryos has also been 
investigated128. By using advanced genetic tools it has been shown that mural cells are recruited by 
arterial-fated vessels and that this process is strictly dependent on selective hemodynamic-
dependent arterial Notch signalling. This flow-dependent Notch activation and the associated 
endothelial genetic program are driven by endothelial primary cilia as determined by tissue-specific 
CRISPR gene targeting. Ultimately, zebrafish foxc1b was identified as a cilia-dependent Notch 
specific target that is required in endothelial cells to drive mural cell coverage in a flow-dependent 
manner128. These data offer a novel hemodynamic-dependent mechanism driving vascular 
myogenesis in developing vasculature that may provide a new and better understanding of 
endothelial and mural cell interaction in health and in disease. 
Most studies in zebrafish that have examined vascular disease have focused on endothelial 
patterning and blood components130. However, the SMC developmental homology between 
zebrafish and mammals and the potential advantages of high-resolution imaging and tissue-specific 
genetic approaches raise the prospect of using the zebrafish to study the genetics of vascular SMC-
related human diseases. It has been shown that in zebrafish mural cells surrounding brain central 
arteries are Notch3 dependent for proliferation and integrity64. Zebrafish Notch3 mutants display 
both cerebral hemorrhages and pericyte loss supporting a mechanism whereby in zebrafish Notch3 
promotes mural cell integrity and models CADASIL human disease.  
Challenges to such an approach in zebrafish may include the relative sparsity of mural cells in the 
zebrafish vasculature, the low pressure arterial environment and the lack of optical clarity in adult 
fish. Nevertheless, the zebrafish model has been used to provide insights into thoracic aortic 
aneurysm development. Rare variants in MAT2A and FOXE3 have been identified that were 
associated with familial thoracic aneurysms131,132. Knockdown of the orthologous gene in zebrafish 
led to abnormalities in aortic arch development, which were rescued by the wild type human MAT2A 
or FOXE3 to a greater extent than by the mutant versions. It wasn’t clear in these studies whether 
the defect was solely in endothelial cell patterning or whether there were primary defects in the 
developing arch mural cells. However, FOXE3 was investigated further in a mouse model which 
showed reduced medial SMC numbers, density and SMC marker expression in the ascending aorta 
and arch along with an increased propensity to SMC death and rupture in response to transverse 
aortic constriction. More detailed studies of the role of mural cells in zebrafish models of aortic 
aneurysms would clarify the utility of the zebrafish system for SMC disease modelling. 
There are some limitations with the zebrafish system as mentioned above with a relative sparsity of 
mural cell density and loss of optical clarity in adults. In addition, mammalian antibodies frequently 
do not cross react with fish antigens and require either the development of fish-specific antibodies 
or the use of in situ hybridisation or transgenic reporter techniques. Finally, genome duplication 
events after evolutionary divergence of zebrafish and land-based invertebrates results in either a 
lack or duplication of orthologous human genes133. Accordingly, the absence of conditional knock-
out and knock-in technology still represents a weakness of this model system.  Despite these issues, 
the many advantages of the zebrafish system render it a powerful and exciting new model for 
studying the role of mural cell lineage on vascular development and disease. 
 
6. Summary and Conclusions 
A key question in vascular biology is how the diversity of origin of mural cells influences vessel 
properties, in particular the regional propensity to vascular diseases. There is now increasing 
evidence that the mechanisms regulating development and function of distinct vascular regions 
depends on their embryological origins. Moreover, pathological responses appear to be influenced 
by the origin of the SMC or pericytes involved. The challenge to the field is to identify in detail the 
effects of mural cell lineage as distinct from other undeniably important factors such as prevailing 
haemodynamics and vessel wall structure. To facilitate these studies, we have highlighted 2 new 
models. First, human PSCs enable the generation of lineage specific SMC in vitro, providing 
opportunities for comprehensive in vitro analyses of development and disease on a human genetic 
background. Secondly, the zebrafish model combines the power of an in vivo system with 
unmatched access to live imaging of the developing vasculature. These and other model systems 
offer the prospect of new understanding of disease mechanisms and new therapies for a range of 
vascular diseases. 
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Figure legends 
Figure: 1. Schematic representation of vascular mural cell origin during development.  
Fate mapping studies identify a highly mosaic distribution of mural cells with different 
developmental origins for vascular smooth muscle and pericytes. Neural crest cells contribute to 
mural cells of the aortic root, ascending aorta, arch and branches as well as pulmonary trunk (not 
shown). Lateral plate mesoderm (LPM) gives rise to secondary heart field and the base of the aortic 
root, as well as to the proepicardium. The proepicardium is a developmentally complex structure 
that also has origins from the septum transversum (ST), a rostral mesodermal structure that folds to 
lie between the developing heart and liver. During early cardiac development, the proepicardium 
forms the epicardium, a mesothelial structure around the developing heart, which contributes to the 
coronary arteries and to coronary pericytes. Paraxial mesoderm (PM) gives rise to the somites, which 
contribute to the descending aorta and its distal branches.  
 
Figure 2: Thoracic and abdominal aortic aneurysms.  
Aortic aneurysms, caused by weakness and dilatation of the vessel wall, are commonly seen in the 
aortic root and ascending aorta or in the abdominal aorta. Thoracic aneurysms are prone to 
dissection; classified as type A for those that involve the ascending aorta and arch and type B when 
only the descending aorta is involved. The sites of dissection (arrows) occur frequently at the 
sinotubular junction or at the aortic isthmus, regions where there is juxtaposition of SMC of different 
embryonic origins. 
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